WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that David A. Hosford, M.D., Ph.D., Targacept’s Vice President of Clinical Development, is scheduled to present data from Targacept’s Phase 2 trial of TC-5619 in cognitive dysfunction in schizophrenia at the 13th International Congress on Schizophrenia Research (ICOSR) being held in Colorado Springs, Colorado from April 2 through April 6, 2011.
